4.5 Editorial Material

The Race to Develop the Pfizer-BioNTech COVID-19 Vaccine: From the Pharmaceutical Scientists' Perspective

Related references

Note: Only part of the references are listed.
Article Economics

Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Manuela Di Fusco et al.

Summary: This study evaluated the public health impact and cost savings of the Pfizer-BioNTech COVID-19 Vaccine during its first year rollout in the US, estimating millions of COVID-19 cases prevented and billions of dollars saved in healthcare costs.

JOURNAL OF MEDICAL ECONOMICS (2022)

Review Biochemistry & Molecular Biology

mRNA vaccine for cancer immunotherapy

Lei Miao et al.

Summary: mRNA vaccines have emerged as a promising platform for cancer immunotherapy, showcasing high potency, safe administration, rapid development potentials, and cost-effective manufacturing. However, challenges such as stability, innate immunogenicity, and inefficient in vivo delivery restrict their applications. In addressing these challenges, structural modifications and formulation methods are being researched to enhance the anti-tumor immune response.

MOLECULAR CANCER (2021)

Review Nanoscience & Nanotechnology

Lipid nanoparticles for mRNA delivery

Xucheng Hou et al.

Summary: Lipid nanoparticle-mRNA formulations have successfully entered clinical use as COVID-19 vaccines, representing a major milestone in mRNA therapeutics. This review discusses the design of lipid nanoparticles for mRNA delivery, emphasizing key points for clinical translation and preclinical studies of lipid nanoparticle-mRNA therapeutics for various diseases.

NATURE REVIEWS MATERIALS (2021)

Article Multidisciplinary Sciences

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Jesper Pallesen et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)